



Arsanis expands its anti-infective monoclonal antibody programs with additional grant support from FFG and EUROSTARS

Vienna (Austria), September 10, 2012 – Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections. Both grant supports involve the Austrian Research Promotion Agency (Österr. Forschungsförderungs GmbH or “FFG”), the leading public funding agency for applied research in Austria.

An EUR 1.54 million FFG support, is given for the 2nd year of a 4-year “Basisprogramm” project with a total budget of EUR 12.5 million (with up to 70% funding). A EUROSTARS grant with EUR 4.55 million - mainly funded by national agencies - is awarded to the KLEBSICURE consortium with Arsanis as consortium leader, and GATC GmbH (Constance, Germany), the Max Planck Institute for Infectious Biology (Berlin, Germany) and the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy (Wroclaw, Poland) as consortium members.

“Arsanis is building a broad portfolio of anti-infective antibodies against bacterial infections,” commented Eszter Nagy, MD, PhD, Co-founder and Chief Scientific Officer of Arsanis. “The continued support from FFG’s Basisprogramm is based on the progress of our antibody discovery efforts towards companion diagnostics and monoclonal antibody based therapeutics against severe infections caused by *Staphylococcus aureus* and multi-drug resistant *Escherichia coli*. It will significantly contribute to the timely delivery in the pre-clinical testing of our product candidates and to initiate GMP manufacturing. The EUROSTARS grant and the excellent consortium partners will accelerate the speed of discovery of monoclonal antibody based products targeting multi-drug resistant *Klebsiella pneumoniae*.”

“Arsanis has assembled a consortium of excellent partners to target an important emerging pathogen,” said Tillman Gerngross, Ph.D. Co-Founder and Chairman of Arsanis, Inc. “Over the past 18 months Eszter and her team have built an impressive portfolio of programs in the infectious disease space and the most recent grant support further validates our approach.”

“These grants will help to reinforce Vienna as an attractive venue for international biotech investors,” said Errik Anderson, Arsanis Co-founder. Arsanis received funding in 2010 by a syndicate of three US-based venture capitalists; OrbiMed Advisors (New York, NY), Polaris Venture Partners (Waltham, MA), and SV Life Sciences (Boston, MA).

About Arsanis

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with high mortality in spite of low rates of antibiotic resistance. Using first-in-class monoclonal antibody discovery technologies that support the selection of highly potent antibodies with unique qualities, Arsanis is building a broad portfolio of infectious disease targets. The most successful pre-clinical programs will be advanced into clinical proof-of-relevance studies.



Arsanis was founded in the fall of 2010 by Dr. Eszter Nagy (former SVP of Research at Intercell, AG), Dr. Tillman Gerngross (Co-founder and CEO of Adimab, and Co-founder and CSO of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) and Errik Anderson (Co-founder and COO of Adimab) who bring together expertise in monoclonal antibody discovery, infectious disease biology and commercializing innovation. Arsanis Biosciences GmbH, based in Vienna, Austria, is a wholly owned subsidiary of Arsanis, Inc.

For more information, visit www.arsanis.com.

Contact

Barbara Grell
Senior Manager Public Relations, Arsanis Inc.
E: barbara.grell@arsanis.com
T: +43-676-898543700

The Eurostars Programme is powered by
EUREKA and the European Community

